Jacek Kiljański
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Diabetes Management and Research, Metabolism, Diabetes, and Cancer, Diet and metabolism studies, Thyroid Disorders and Treatments
Most-Cited Works
- → Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial(2012)156 cited
- → The Ocular Muscle Cell Is a Target of the Immune System in Endocrine Ophthalmopathy(1995)52 cited
- → Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study(2015)48 cited
- → Introduction of biosimilar insulins in Europe(2017)41 cited
- → Biosimilar insulins: a E uropean perspective(2014)30 cited
- → Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes(2018)27 cited
- → Should Graves' Disease be Considered a Collagen Disorder of the Thyroid, Skeletal Muscle and Connective Tissue?(1995)26 cited
- → Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study(2013)23 cited
- → Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme(2023)20 cited
- → Glycaemic outcomes of an I ndividualized treat M ent a P proach for old ER vulnerable pat I ents: A randomized, controlled st U dy in type 2 diabetes M ellitus ( IMPERIUM )(2017)20 cited